Artemisia ludoviciana Nutt. (Asteraceae) is widely used in Mexican folk medicine for treating inflammation, diabetes and painful complaints. The in vivo antinociceptive, antiinflammatory and antihyperalgesic activities of an aqueous extract (AE) of the plant were investigated using well-known animal models. AE reduced the licking time in the formalin test in healthy and NA-STZ mice; the activity was better during the inflammatory phase; accordingly, it displayed significant antiinflammatory when tested at the same doses using the carrageenan-induced oedema model. AE also produced a significant dose-dependent antinociceptive effect in the hot plate test at 100 and 316 mg/kg (p.o.). Phytochemical analysis of the non-polar fraction of AE resulted in the isolation of two major lactones [achillin (1) and dehydroleucodin (2)], which showed antiinflammatory effect, being 2 the most active at 17.7 mg/kg. A suitable analytical method was successfully developed and validated to quantify 1 and 2. Altogether, these results tend to support the medicinal uses of the plant.
Artemisia ludoviciana Nutt. (Asteraceae) is a popular bitteraromatic herb valuable for its reputed efficacy for treating gastrointestinal, inflammatory and painful disorders, as well as obesity and type 2 diabetes mellitus [1a,b] . Antibacterial, antiprotozoal, antidiarrheal and spasmolytic activities of the aerial parts extracts have been previously reported [1c-1f] . More recently, it was demonstrated the antidiabetic effect of traditional preparations and compounds from this plant [1g] and the ability of its essential oil for attenuating neurogenic pain [1h] . Phytochemical investigations of this species have resulted in the isolation of monoterpenoids, sesquiterpene lactones and flavonoids [1i-1m, inter alia]. As a part of our efforts to establish the efficacy and quality control parameters of selected Mexican medicinal plants, herein reported the investigation of the anti-inflammatory and antinociceptive effects of an infusion and compounds from A. ludoviciana, and the development of a suitable procedure to quantify some active compounds.
The formalin test involves the assessment of behavioral responses to chemically induced noxious stimuli; this model is widely used to detect potential analgesic agents and to elucidate primarily their mechanism of action. The dose regime and protocols were based on previous reports [2a,b] . As shown in Figure 1 , animals pre-treated with AE at the dose of 316 mg/kg displayed a significant antinociceptive effect during the inflammatory phase, indicating that the traditional preparation contained substances that might modify the production or release of some inflammatory mediators involved in the second phase. Furthermore, oral administration of AE significantly inhibited the formation of carrageenan-induced oedema ( Figure 2 ). This test is widely used for determining the biphasic events of inflammation. Thus, at the dose of 31.6 mg/kg, the antiinflammatory effect was observed only 3 and 4 hours after carrageenan administration; at the dose of 100 mg/kg, from the first hour, and at the dose of 316 mg/kg since the third hour to the end of the experiment. The effect was comparable to that of the positive control group (DIC, 31.6 mg/kg, p.o.) . These results were consistent with the effects observed during the second phase of the formalin test. The antihyperalgesic potential of AE in mice in a hyperglycemic state induced with nicotinamide-streptozotocin (NA-STZ, 50 mg/kg-130 mg/kg) [2c] was assessed also using the formalin test. Pre-treatment with NA-STZ reduces the pain threshold to chemical stimulation with formalin mediated by C fiber nociceptors, increment in cyclooxygenase-2 expression, and consequently in prostaglandin E2 release [2d] . Figure 3 shows that oral administration of AE (316 mg/kg) attenuated the licking time in both neurogenic and inflammatory phases in hyperglycemic mice. The doses of 31.6 and 100 mg/kg reduced the licking time only during second phase, consistent with an antihyperalgesic effect mediated at central and peripheral levels. Gabapentin (GBP), the positive control, showed the same trend of effects.
To confirm the central effect of AE in hyperglycemic-hyperalgesic mice, the hot plate test was used. This test is the most common thermal stimuli nociception model used for evaluating central analgesic efficacy of drugs [2e] . AE at the doses of 100 and 316 mg/kg showed a significant dose-dependent analgesic effect improving the hyperalgesic state in hyperglycemic-hyperalgesic mice (Figure 4) by mechanisms yet be determined. In order to rule out that the behavioral responses observed in the hot plate and formalin tests were not due to motor dysfunction or changes in the exploratory behavior or general activity, the animals were subjected to the rota-rod and open field tests. Thus, administration of AE in normal mice using the rota-rod and open field assays indicated that healthy mice pre-treated with AE (316 mg/kg) did not show detectable relaxant or sedative effects at the highest dose tested. On the contrary, diazepam (DZP, 4 mg/kg) used as a reference drug, reduced significantly the time the animals spend on the rota-rod or the number of line-crossings in the open field-test ( Figure S6 ). Fractionation of AE by partitioning with hexane and ethyl acetate, yielded fractions F-H and F-E, respectively.
Both fractions were active when testing with the formalin test at the dose of 316 mg/kg ( Figure 1 ). HPLC analysis of F-H and F-E revealed the presence of two major common compounds, namely achillin (1) and dehydroleucodin (2) [3a] . HPLC separation of F-H yielded 1 and 2 in sufficient amount for pharmacological testing. The antinociceptive potential of compounds 1 and 2 were analyzed next using the formalin test. The results revealed that compound 2 was the most active ( Figure S5) ; as in the case of AE, the best effect was observed in the inflammatory phase of the response. The action of 2 could be mediated by the inhibition of the transcription factor NF-kB, according to previous in vitro studies [2f] . Further investigation is required to establish the mechanism of action underlying the antinociceptive action of both lactones.
Finally, an UPLC-ESI/MS method for quantifying achillin (1) and dehydroleucodin (2) in AE was developed ( Figure S7 ) and validated according to the International Conference on Harmonization guidelines [2g] . Standard curves of the two compounds had acceptable linearity (Table 1 ) in the range of 5 -200 g/mL with correlation coefficients > 0.998. The limit of detection (LOD: S/N = 3) and quantification (LOQ: S/N = 10) values were 0.64 g/mL and 1.94 g/mL for compound 1, and 0.47 g/mL and 1.45 g/mL for compound 2. The precision of the method (intraday and interday) was determined, and the relative standard deviations (%RSD) values were less than 1.1% and 2.0%, for 1 and 2, respectively (Table 1) . Thus, the method developed is reliable and accurate and could be applied to identify and quantify achillin (1) and dehydroleucodin (2) in A. ludoviciana.
In summary, the present study demonstrated for the first time that an infusion from the aerial parts of A. ludoviciana exerted significant antinociceptive, antiinflammatory and antihyperalgesic effects in normal and hyperglycemic mice. These pharmacological actions tend to support some of the medicinal traditional uses of the plant to alleviate painful complaints. Compounds 1 and 2 were found to be some of the major active principles. In addition, an UPLC-ESI/MS method was developed and validated and could be used for the quality control of this widely commercialized medicinal plant. (2) were isolated from A. ludoviciana as described and their structures and purity were confirmed by NMR, MS and UPLC.
Experimental

Plant material and sample preparation:
UPLC-ESI/MS analyses:
The analyses were performed on a Waters Acquity UPLC-H Class system (Milford, MA, USA) equipped with a quaternary pump, sample manager, column oven, and PDA detector interfaced with a SQD2 single-quadrupole mass spectrometer equipped with an electrospray ion source. MassLynk software version 4.1 was used to control the UPLC-ESI/MS system and for data acquisition and processing. The analytical method was developed using a BEH C-18 column (1.7 m, 100 × 2.1 mm, Waters, USA). The mobile phase consisted of water (0.1% formic acid; A) and acetonitrile (B), with a gradient elution as follow: 0−4 min, 15% B; 4−6 min, 35% B; 6−9 min, 85% B; 9−12 min, 100% B. The column was equilibrated with 15% B for 2.5 min before the next injection, and detection was carried out using a PDA detector at 270 nm. The flow rate was 0.3 mL/min, injection volume was 3 L; column temperature was 40°C. For the identification of compounds, the PDA detector was set from 220 to 400 nm; while MS parameters were as follows: the cone and capillary voltages were set at 30.0 V and 3.7 kV, respectively; the source temperature was 400°C and the desolvation temperature was 650°C. ESI/MS spectra were obtained using nitrogen as the collision gas, within a mass range of m/z 100-1000 (scan duration of 0.5 s). Each sample was analyzed in both positive (ESI + ) and negative (ESI − ) modes to provide better information for structural identification ( Figure S7 ).
Method validation:
The developed UPLC method was validated in accordance with the International Conference on Harmonization [ICH Q2(R1)] guidelines in terms of linearity, precision, detection limit (LOD), quantification limit (LOQ), and recovery [2g]. For linearity, the standard solutions for the calibration curves of 1 and 2 were prepared by stepwise dilution of the stock solutions with methanol at five concentration levels within the range of 5 to 200 g/mL. The regression coefficient, slope and intercept were calculated from the calibration curves using GraphPad Prism software version 5.0. LOD (S/N = 3) and LOQ (S/N = 10) for each standard were determined by injecting the serially diluted standard solutions and were calculated by the UPLC-ESI/MS system suitability software. For intra-day precision (repeatability), each standard was analyzed at three different concentrations in triplicate within one day. While for inter-day precision (intermediate precision), each standard was analyzed at three different concentrations in triplicate for two consecutive days. The precision data were expressed as relative standard deviation (%RSD). The accuracy of the analytical method was established by a recovery experiment adding a known amount of individual standard into F-E sample (50 g/mL). The mean percentage recovery for 1 and 2 were found to be between 98 and 102% by means of Fisher's F-test [2g].
Animals: ICR male mice, weighting between 20 and 25 g, were purchased from Centro UNAM-Envigo RMS (Envigo RMS, S.A. de C.V., Mexico City, Mexico) and kept in an environmentally controlled room maintained at 22°C with alternating 12 h light/dark natural cycle, with free access to rodent pellet diet and water ad libitum. All studies were conducted according to the Mexican Official Norm for Animal Care and Handling (NOM-062- ZOO-1999) with the approval of the Institutional Ethical Committee for the Use of Animals in Pharmacological and Toxicological Testing, Facultad de Química, UNAM (FQ/CICUAL/233/17 and FQ/CICUAL/232-2/17).
Nicotinamide-streptozotocin induced hyperglycemia in mice:
The hyperglycemic state in mice was induced by a single intraperitoneal injection of 50 mg/kg of NA followed by 130 mg/kg of STZ in 100 mM citrate buffer (pH 4.5) as previously described [1g] . After fourteen days, mice having blood glucose higher than 200 mg/dL were considered hyperglycemic [3b].
Analgesic activity assay: Formalin test:
The formalin assay was assessed according to Hunskaar and Hole [3c] . Healthy or hyperglycemic animals were divided into five groups (I-V) containing six animals each. Groups I and II [vehicle and reference drugs (GBP or DIC, 31.6 mg/kg)] as well as those of groups III-V and were administered subcutaneously on the dorsal surface of the right hind paw with 20 L of AE at the doses of 31.6, 100, and 316 g/paw. Thirty min after treatment administration mice received an injection of 30 L of formalin (2 or 1%, respectively) by using a micro syringe with a 30-gauge needle. All animals were put into a chamber and observed. Based on the response pattern, two distinct periods of intensive licking activity were identified and scored separately. The first period (neurogenic phase) was recorded 0-10 min after the injection of formalin and the second period (inflammatory phase) was recorded 15-30 min after administration. Compounds 1 and 2 (10, 17.7, and 31.6 mg/kg) were evaluated only in healthy mice following a similar protocol. The positive control was DIC and the solution of formalin used was that at 2%.
Analgesic activity assay: Hot plate test:
The conventional hot plate apparatus (Ugo Basile, Italy) was used to measure the nociceptive response. Briefly, NA-STZ hyperglycemic mice were placed into an acrylic cylinder on the heated surface (55 ± 0.2°C) and the latency time to respond to the thermal stimulus was evaluated as the time taken to lick, lift, shake or stamp any of the hind limbs or jump. A cut off time of 30 s was used to avoid damage to the animals paw. AE was administered to the animals at 31.6, 100, and 316 mg/kg doses. The control group received vehicle (2% Tween 80 in 0.9% saline solution) and the reference group MOR (5 mg/kg). Mice were placed on the heated plate 30, 60, 90 and 150 min after treatment [2e].
Antiinflammatory activity assay:
Carrageenan induced paw oedema test was performed as described by Winter et al. [3d] . Briefly, healthy mice were randomly divided into groups of six mice each. After 30 min of the treatments administration (vehicle, DIC or AE) inflammation was induced by injection of 30 L of 1% w/v, carrageenan in 0.9% saline solution into the sub plantar area of the right hind paw of mice. Paw volumes were measured using a Plethysmometer (Ugo Basile 7150, Italy) before and hourly interval from 1-6 h after carrageenan injection. The mean hourly oedema for each group and the total mean oedema for the 5 h observation period were calculated as described previously [3e] .
Behavioral activity assay: Rota-rod test:
The rota-rod test was performed according to the method described by Dunham and Myia [3f] . Briefly, the mice were trained for 3 days on the rota-rod (Ugo Basile 7600, Italy) at a constant speed of 16 rotations per minute (rpm), according to their ability to remain on the rotating bar without falling for at least 3 min. On the test day (24 h after the final training trial), 30 min before the assay, the mice were divided into groups (n = 6) and pre-treated with vehicle (2% Tween 80 in 0.9% saline solution), AE (316 mg/kg) or diazepam (DZP, 4 mg/kg, i.p.). The animals were tested at 30, 45, and 60 min after the treatments, and the time the mice remained on top of the bar was recorded at a maximum of 180 s.
Behavioral activity assay: Open field assay: Animals were placed individually on the center of an acrylic container (20 × 40 × 15 cm) and divided in eight equal squares; locomotor activity was measured by counting the number of squares crossed with all paws (line-crossings) during a 2 min period. Animals were treated with vehicle (2% Tween 80 in 0.9% saline solution), AE (316 mg/kg), or DZP (4 mg/kg, i.p.) 30 min before the test.
Statistical analysis:
Data are the mean ± standard error of the mean (SEM). Statistical significances (p < 0.05, 0.01 or 0.001) of the differences among groups were analyzed by a one-way analysis of variance (ANOVA), followed by Dunnett′s post hoc test. GraphPad Prism program version 5.0 (GraphPad Software, San Diego, CA, USA) was used for the data analysis.
Supplementary data: 1 H and 13 C NMR spectral data for compounds 1 and 2 are available. Data of analgesic activity assay (Formalin test) of 1 and 2 as well as behavioral activity assay of AE are also available. UPLC chromatogram of F-E detected at 270 nm and mass spectra for selected peaks.
